FDA Approves Orally Disintegrating Nilotinib (Cavhanza) for Chronic Myeloid Leukemia

FDA Approves Orally Disintegrating Nilotinib (Cavhanza) for Chronic Myeloid Leukemia

The FDA has approved Cavhanza, an orally disintegrating tablet (ODT) formulation of nilotinib, for the treatment of select patients with chronic myeloid leukemia (CML). This new formulation enhances patient convenience by allowing co-administration with acid-reducing agents and reducing food-related burdens. For the CML therapeutics market, the approval removes a key dosing barrier that has constrained nilotinib's competitive positioning against rival tyrosine kinase inhibitors — and signals that formulation innovation remains a viable lifecycle management strategy in oncology.

Key Takeaways

• The FDA has approved Cavhanza, the first orally disintegrating tablet formulation of nilotinib, for adult patients with Philadelphia chromosome-positive chronic myeloid leukemia.
• The ODT formulation is designed to maintain the drug's bioavailability while enabling concomitant use of proton pump inhibitors and H₂ receptor antagonists, and can be taken without regard to meals.
• Clinical data show six-year overall survival and progression-free survival rates of 96% for nilotinib, with a cumulative major molecular response rate of 98%.
• The approval gives the nilotinib franchise a formulation-based counter-narrative in an increasingly competitive TKI class headlined by asciminib's recent accelerated approval.

What the Cavhanza Approval Means for the CML Market

The FDA's approval of Cavhanza addresses a practical limitation that has quietly eroded nilotinib's competitiveness in the CML treatment paradigm. Standard nilotinib capsules require fasting conditions and cannot be co-administered with acid-reducing agents — restrictions that complicate treatment for patients managing gastrointestinal comorbidities or those on long-term proton pump inhibitor therapy. The ODT formulation eliminates both constraints, giving prescribers a reason to reconsider nilotinib in treatment algorithms where it may have been passed over for more conveniently dosed alternatives.

Nilotinib capsules are indicated for adult and pediatric patients aged one year and older with newly diagnosed Ph+ CML in chronic phase, as well as for adult patients with chronic phase and accelerated phase Ph+ CML resistant to or intolerant to prior imatinib therapy. The label also covers pediatric patients with Ph+ CML-CP resistant or intolerant to prior tyrosine-kinase inhibitor therapy. Cavhanza's approval brings these established indications into a more patient-friendly dosage form.

The competitive context matters. The CML TKI class has seen intensifying competition, including the FDA's accelerated approval of asciminib for newly diagnosed CML — a drug positioned as a next-generation option with a differentiated mechanism of action. Cavhanza's approval gives nilotinib a formulation-based counter-narrative: same proven molecule, fewer administration hurdles.

How Strong Is the Clinical Case for Nilotinib?

The long-term efficacy data supporting nilotinib are difficult to dismiss. A phase 2 trial with nilotinib 400 mg twice daily reported six-year overall survival and progression-free survival rates of 96%, with only one death occurring after progression to blast phase. At the six-year mark, 75% of patients remained on nilotinib therapy — a retention figure that speaks to both tolerability and sustained clinical benefit.

The cumulative incidence of major molecular response was 98%. Only one patient had a confirmed loss of major molecular response. These numbers reinforce nilotinib's position as a high-efficacy second-generation TKI, particularly in the newly diagnosed chronic phase setting, where deep molecular response correlates with long-term disease control.

Fatigue is a common symptom among people with CML. Bone marrow crowded by large numbers of abnormal white blood cells cannot produce enough red blood cells, leading to anemia-related fatigue. Achieving deep molecular responses addresses this disease burden by restoring more normal hematopoiesis.

How Should Investors and BD Teams Read This Approval?

Cavhanza's approval illustrates how formulation innovation can unlock commercial value for mature molecules in competitive oncology markets. The ability to co-administer with PPIs and dose without regard to meals removes two practical barriers that have historically limited nilotinib's uptake — barriers that did not exist for some competing TKIs with fewer administration restrictions.

For BD teams, the approval underscores a broader trend: reformulation can extend a product's commercial runway without requiring new clinical trials or novel mechanisms. In CML specifically, where patients remain on TKI therapy for years or even decades, adherence-driven formulations carry a stronger value proposition than in indications with shorter treatment durations.

Investors and analysts should monitor market adoption rates, competitive responses, and any potential label expansions or new indications. The ability to co-administer with acid-reducing agents addresses a genuine unmet need in clinical practice, where a meaningful subset of CML patients require long-term gastric acid management — a population that previously faced a trade-off between symptom control and optimal TKI absorption.

Frequently Asked Questions

Related profiles

• nilotinib

Related coverage

• FDA Approves Ensitrelvir for Post-Exposure Prophylaxis of COVID-19